00:13Let's get started.
00:39Tuberculosis is a dangerous disease, which has been since 100 years before and is still
00:51running. This cause is a bacteria, which is called Mycobacterium tuberculosis. Today,
00:59about 1 hour, 500 people have died worldwide. This is the first single pathogen, which
01:11can cause many deaths. This treatment is available, which is called Muddy Drug Therapy, which
01:21is 4 months ago, and in the rest of the 4 months, it is a regimen. This is effective, but
01:36because
01:37TB, especially the pulmonary TB, which is the most common form, although TB can happen in
01:44any organ of the body, where you can cause tuberculosis, but most common, especially in adults,
01:52it is in the lungs and it is infectious, but as it is used in 15 days, it is non
01:59-infected.
02:08So, we are working mainly on vaccines. In my lab, we have a certain protein family, which
02:20have 50 different proteins. When bacteria go to the body, which we call latency and dormancy,
02:29which is called latency and dormancy, which is called latency and dormancy, we call it
02:37as peptides. These are known as dosar protein vaccines. We also call them as subunit vaccines.
02:49which we have created, which we have created. We have TB patients' blood
02:56to take our blood, which we have exposed to our proteins, which we have exposed to
02:59and we have seen that they have immune response produced in bacteria. So, in the
03:07beginning of the beginning, we all have a great immune response response to our proteins and
03:13which we have created. So, we have created a subunit vaccine design team, which we have
03:19cloned, expressed, and it is available in a multi-epitop protein. It is available in our
03:26case, which we have tested in mice. We call it prime boost strategy, which we have
03:53in a special equipment, which is available at ICGV New Delhi. We have immunized mice,
04:04which we have exposed to TB patients and we have seen that they have
04:08in a special equipment, in a special set-up which is available at ICGV New Delhi.
04:08So, there are two parts of covid vaccines that we have donated to
04:10dear to our patients. So, luckily, we have the two parts of our patients, which we have
04:18in another pathology. We have found that our patients, and our vaccines there are
04:40and we have patented this vaccine.
04:45We have established a research lab here.
04:50I joined Meranda House in 2009,
04:52and then we will research on tuberculosis.
04:55Although tuberculosis research is my PhD,
04:58so when I joined my senior colleague,
05:03Professor Saadhana Sharma,
05:04I joined this team,
05:07and then we established this lab.
05:09Now we are working on ICMR funded projects.
05:14My major work is a special family of proteins,
05:18which is mycobacterium tuberculosis.
05:20You know that mycobacterium tuberculosis is a causative bacteria,
05:24which causes TB.
05:26So this particular bacteria is a family of proteins,
05:35which is called 1% genome.
05:38So these proteins are very interesting,
05:41and they are more restricted to pathogenic bacteria,
05:45and they have evolved with time.
05:48So this is a very interesting family.
05:51And when we are studying these proteins,
05:54we are studying these proteins,
05:56and they are also trying to know their structure
05:57and functions.
06:00So we are working on two types of proteins.
06:03We are looking for these proteins,
06:05so we are looking at how to create a role for human cells,
06:08what host cell's,
06:09different organelles,
06:11like mitochondria,
06:12endoplasmic reticulum,
06:14cell death pathways,
06:15and how to modulate them,
06:18smaller the immune system,
06:20and small the cellular defenses.
06:22This is very important because we don't know which proteins that help the bacteria to kill the host's defense, so
06:34we won't win on it.
Comments